| __timestamp | Dynavax Technologies Corporation | ImmunityBio, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 4326000 |
| Thursday, January 1, 2015 | 22180000 | 226206000 |
| Friday, January 1, 2016 | 37257000 | 94391000 |
| Sunday, January 1, 2017 | 27367000 | 53821000 |
| Monday, January 1, 2018 | 64770000 | 35463000 |
| Tuesday, January 1, 2019 | 74986000 | 46456000 |
| Wednesday, January 1, 2020 | 79256000 | 71318000 |
| Friday, January 1, 2021 | 100156000 | 135256000 |
| Saturday, January 1, 2022 | 131408000 | 102708000 |
| Sunday, January 1, 2023 | 152946000 | 129620000 |
Infusing magic into the data realm
In the ever-evolving biotech industry, understanding financial trends is crucial for investors and stakeholders. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of two prominent companies: ImmunityBio, Inc. and Dynavax Technologies Corporation, from 2014 to 2023.
Over the past decade, Dynavax Technologies has seen a steady increase in SG&A expenses, peaking in 2023 with a 760% rise from 2014. ImmunityBio, Inc., on the other hand, experienced a more volatile trajectory, with a significant spike in 2015, marking a 5,130% increase from the previous year. By 2023, ImmunityBio's expenses were approximately 30% lower than their 2015 peak.
These trends highlight the strategic financial decisions made by each company, reflecting their growth strategies and market positioning. Investors should consider these patterns when evaluating potential opportunities in the biotech sector.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and ImmunityBio, Inc.
SG&A Efficiency Analysis: Comparing Sanofi and Dynavax Technologies Corporation
argenx SE and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Dynavax Technologies Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and ImmunityBio, Inc.
Comparing SG&A Expenses: Catalent, Inc. vs ImmunityBio, Inc. Trends and Insights
Breaking Down SG&A Expenses: Blueprint Medicines Corporation vs ImmunityBio, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Dynavax Technologies Corporation
Comparing SG&A Expenses: ImmunityBio, Inc. vs MannKind Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing ImmunityBio, Inc. and Taro Pharmaceutical Industries Ltd.
Breaking Down SG&A Expenses: ImmunityBio, Inc. vs Travere Therapeutics, Inc.
Breaking Down SG&A Expenses: Protagonist Therapeutics, Inc. vs Dynavax Technologies Corporation